Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Drug Chem Toxicol ; 45(5): 2233-2245, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-33934680

RESUMEN

Statins are 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor drugs that lead to serum-cholesterol-lowering effects. Rosuvastatin, a third-generation statin, has shown better results in reducing cholesterol concentrations when compared to other widely prescribed statins. Recent studies by our group reported that rosuvastatin impairs reproductive function in rats possibly by disrupting the reproductive-endocrine axis. In this study, we evaluated whether rosuvastatin presents estrogenic or antiestrogenic effects, by an in vivo uterotrophic assay in rats, and investigated the direct effect of this drug upon rat uterine tissue contractility both in non-gravid and gravid periods. Rosuvastatin exposure in vivo at doses of 0 (control), 3, and 10 mg/kg/d was not associated with estrogenic or antiestrogenic effects on uterine tissue. However, in vivo (doses of 0, 3, and 10 mg/kg/d) and ex vivo (concentrations of 0, 1, 10, and 100 µg/mL) exposures to this drug were related to alterations in uterine basal contraction pattern. Furthermore, in vivo and ex vivo rosuvastatin exposures potentially modulate the action of uterine contraction inducers carbachol, norepinephrine, and prostaglandin E2. Thus, rosuvastatin can affect uterine physiology not necessarily by an endocrine mechanism related to the estrogen signaling, but possibly by its pleiotropic effects, with indirect tissue and cellular interactions, since in vivo and ex vivo exposures of uterine fragments to rosuvastatin presented different responses in uterine contractile parameters, which require further studies upon the precise mechanism of action of this drug in female reproductive function.


Asunto(s)
Estrógenos , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Animales , Colesterol , Estrógenos/toxicidad , Femenino , Inhibidores de Hidroximetilglutaril-CoA Reductasas/toxicidad , Embarazo , Ratas , Ratas Wistar , Rosuvastatina Cálcica/toxicidad
2.
J Appl Toxicol ; 40(7): 947-964, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32072669

RESUMEN

Many obese patients are exposed to hypolipidemic and serotonin-norepinephrine reuptake inhibitor (SNRI) drugs. Statins are one of the most marketed drugs in the world to treat dyslipidemia, while sibutramine, a SNRI drug, is prescribed in some countries to treat obesity and is detected as an additive in many adulterated weight loss supplements marketed worldwide. Previous studies reported adverse effects of isolated exposure to these drugs on male rat reproductive parameters. In the present work, we further investigated male reproductive toxicity of these drugs, administered in isolation or combination in adult rats for a longer period of treatment. Adult male rats (90 days) were treated (gavage) for 70 days with saline and dimethyl sulfoxide (control), sibutramine (10 mg/kg), rosuvastatin (5 mg/kg), or rosuvastatin combined with sibutramine. Sibutramine alone or with rosuvastatin, promoted a reduction in food intake and body weight gain, weight of the epididymis, ventral prostate and seminal vesicle; as well as decreased sperm reserves and transit time through the epididymis; androgen depletion; and increased index of cytoplasmic droplet. The rosuvastatin-treated group showed reduced frequency of ejaculation. Exposure to this drug alone or combined with sibutramine impaired epididymal morphology. Co-exposed rats had altered epididymal morphometry, and seminal vesicle and testis weights. The rats also showed decreased fertility after natural mating and a trend toward a delay in ejaculation, suggesting a small synergistic effect of these drugs. Given the greater reproductive efficiency of rodents, the results obtained in the present study raise concern regarding possible fertility impairment in men taking statins and SNRI drugs.


Asunto(s)
Ciclobutanos/toxicidad , Ciclobutanos/uso terapéutico , Obesidad/tratamiento farmacológico , Fenómenos Fisiológicos Reproductivos/efectos de los fármacos , Rosuvastatina Cálcica/toxicidad , Rosuvastatina Cálcica/uso terapéutico , Testículo/efectos de los fármacos , Adulto , Animales , Humanos , Masculino , Modelos Animales , Ratas , Ratas Wistar
3.
Chem Biol Interact ; 291: 202-211, 2018 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-29953847

RESUMEN

Therapy with betamethasone, a synthetic glucocorticoid, is used in cases of preterm birth risk, in order to promote fetal lung maturation, and decrease neonatal mortality and morbidity. However, late reproductive disorders related to the prenatal exposure to this compound have been reported by our Laboratory, in both male and female rats. Thus, the present study aimed to evaluate the impact of betamethasone on postnatal reproductive development, during pre-puberty, of male offspring exposed in utero to this synthetic glucocorticoid. For this purpose, pregnant Wistar rats were allocated into two groups: Control, treated with saline, and the group treated with betamethasone at 0.1 mg/kg/day. Control and betamethasone groups were treated with intramuscular injection on gestational days 12, 13, 18 and 19, critical days of prenatal reproductive development. The treatment is associated with reduced body and organ weights, disorders in initial reproductive parameters of pre-pubertal male offspring exposed in utero to betamethasone, such as reduction of anogenital distance, alterations in histomorphometric parameters and immunostaining pattern of androgen and estrogen receptors on testicles and epididymides. Our results suggest that prenatal exposure to betamethasone potentially causes reproductive reprogramming and impairs male postnatal reproductive development. This data raise concerns about the use of betamethasone for human antenatal therapy.


Asunto(s)
Betametasona/toxicidad , Epidídimo/patología , Efectos Tardíos de la Exposición Prenatal/patología , Maduración Sexual/efectos de los fármacos , Testículo/patología , Animales , Peso Corporal/efectos de los fármacos , Epidídimo/efectos de los fármacos , Femenino , Masculino , Tamaño de los Órganos/efectos de los fármacos , Embarazo , Ratas Wistar , Receptores Androgénicos/metabolismo , Receptores de Estrógenos/metabolismo , Testículo/efectos de los fármacos
4.
J Toxicol Environ Health A ; 80(19-21): 1166-1179, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28956719

RESUMEN

The acute promyelocytic leukemia (APL) is a rare disease, affecting 0.1/100,000 individuals globally. Despite significant advances in APL therapy, some patients still experience relapsed disease. Currently, arsenic trioxide (As2O3) was found to be effective in relapsed APL treatment and considered as standard treatment for these cases. However, it has been shown that exposure to As2O3 may exert adverse effects on the male reproductive system since this substance might also induce apoptosis of other important cell types including stem cells. Studies demonstrated that treatment with this metallic substance decreased plasma levels of testosterone and interfered with sperm parameters such as concentration, motility, and viability. In addition, As2O3 was found to produce significant damage to spermatocytes, which may be associated with testicular toxicity and consequent inhibition of spermatogenesis. The aim of this study was to determine sub-chronic treatment effects of As2O3 on sperm and testicular morphology, androgen receptor (AR) immunoreactivity in testes and epididymis, in addition to evaluation of fertility parameters in adult male mice. Thirty adult Swiss mice were divided into three experimental groups: control; received distilled water (vehicle) while treated received 0.3 or 3 mg/kg/day As2O3 subcutaneously, for 5 days per week, followed by 2 days of interruption, for 5 weeks. Results showed that As2O3 (1) decreased spermatozoa number, (2) produced seminiferous epithelium degeneration and exfoliation of germ cells tubule lumen (3) altered nucleus/cytoplasm proportion of Leydig cells and (4) reduced AR immunoreactivity in both Leydig and epithelial epididymal cells. Further, fetal viability tests demonstrated an increase in post-implantation loss in females that were mated with As2O3-treated males. Data indicate that As2O3 exposure altered the spermatogenic process and subsequently fetal viability.


Asunto(s)
Viabilidad Fetal/efectos de los fármacos , Óxidos/toxicidad , Testículo/efectos de los fármacos , Animales , Trióxido de Arsénico , Arsenicales/administración & dosificación , Modelos Animales de Enfermedad , Epidídimo/efectos de los fármacos , Epidídimo/metabolismo , Fertilidad/efectos de los fármacos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Células Intersticiales del Testículo/efectos de los fármacos , Células Intersticiales del Testículo/metabolismo , Masculino , Ratones , Óxidos/administración & dosificación , Receptores Androgénicos/metabolismo , Reproducción/efectos de los fármacos , Epitelio Seminífero/efectos de los fármacos , Epitelio Seminífero/metabolismo , Espermatogénesis/efectos de los fármacos , Espermatozoides/efectos de los fármacos , Espermatozoides/metabolismo , Testículo/metabolismo , Pruebas de Toxicidad Subcrónica , Aumento de Peso/efectos de los fármacos
5.
Environ Toxicol ; 32(3): 776-788, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27120489

RESUMEN

Parabens are used as preservatives in cosmetic, pharmaceutical, and food industries, and are frequently detected as contaminants in human fluids and tissues. The endocrine disrupting effects of parabens in female rodents include uterotrophic response, steroidogenesis impairment, and ovarian disturbances. The objective of this study was to determine the effects of maternal butyl paraben (BP) exposure on female sexual development. Pregnant Wistar rats were treated subcutaneously with either corn oil or BP at doses of 10, 100, or 200 mg/kg, from gestational day (GD) 12 until GD 20 for female foetal gonad evaluation, and from GD 12 until the end of lactation to evaluate sexual parameters on the female offspring. Immature female rats were also used in the uterotrophic assay to evaluate the possible estrogenic action of parabens. Our results revealed that, in this experimental protocol, BP did not show estrogenic activity at the doses used and did not impair sexual development and fertility capacity in the female rats, but impaired sexual behavior. We conclude that brain sexual development may be more sensitive to BP effects and we speculate that doses higher than 100 mg/kg (the male lowest observed adverse effect level (LOAEL) for rodent reproductive parameters) would be necessary to promote damages in the female reproduction, regarding the same protocol of exposure. © 2016 Wiley Periodicals, Inc. Environ Toxicol 32: 776-788, 2017.


Asunto(s)
Disruptores Endocrinos/toxicidad , Fertilidad/efectos de los fármacos , Parabenos/toxicidad , Reproducción/efectos de los fármacos , Animales , Estro/efectos de los fármacos , Femenino , Hormonas/sangre , Humanos , Lactancia , Masculino , Exposición Materna/efectos adversos , Tamaño de los Órganos/efectos de los fármacos , Ovario/efectos de los fármacos , Ovario/patología , Embarazo , Ratas , Ratas Wistar , Conducta Sexual Animal/efectos de los fármacos
6.
Oxid Med Cell Longev ; 2016: 4257498, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26839632

RESUMEN

Arsenic trioxide (As2O3) has shown effectiveness in treatment of leukemia but is also associated with reproductive toxicity. Since remediation with N-acetylcysteine (NAC) may mitigate the adverse effects caused by exposure, we assessed the effects of As2O3 and its potential reversibility after exposure cessation or coadministration of NAC. Animals received 0.3 or 3.0 mg/Kg/day of As2O3 subcutaneously and 40 mM of NAC in tap water. As2O3 treatment impaired spermatogenesis and sperm motility and decreased seminal vesicle weight and testosterone serum levels; after suspension of treatment, these parameters remained altered. When NAC was administered, animals showed improvement in sperm parameters and seminal vesicle weight. In vitro epididymal contractility was increased in As2O3-treated animals. We concluded that As2O3 is toxic to the male mouse genital system by compromising sperm quality and quantity; these effects persisted even after suspension of the treatment. However, the coadministration of NAC ameliorates the harmful effects of the drug on the male genital system.


Asunto(s)
Acetilcisteína/administración & dosificación , Arsenicales/administración & dosificación , Epidídimo/efectos de los fármacos , Óxidos/administración & dosificación , Testículo/efectos de los fármacos , Testosterona/metabolismo , Animales , Arsénico/sangre , Trióxido de Arsénico , Arsenicales/efectos adversos , Peso Corporal , Epidídimo/fisiología , Masculino , Ratones , Tamaño de los Órganos , Óxidos/efectos adversos , Distribución Aleatoria , Especies Reactivas de Oxígeno/metabolismo , Motilidad Espermática/efectos de los fármacos , Espermatogénesis/efectos de los fármacos , Espermatozoides/fisiología , Testículo/fisiología , Testosterona/sangre
7.
Reprod Toxicol ; 60: 112-22, 2016 04.
Artículo en Inglés | MEDLINE | ID: mdl-26867865

RESUMEN

Cisplatin (CP) is used to treat a number of cancers, including testicular cancer. Studies indicate that CP-treatment can impair spermatogenesis in humans and rodents by germ cell DNA binding, through different modes of action. CP-paternal exposure resulted in adverse effects in F1 male offspring. In this study, F1 female offspring was assessed for reproductive development after CP-paternal exposure. Peri-pubertal male rats, treated with 1mg/Kg/day of CP or vehicle for 3 weeks, were mated with unexposed females. F1 female offspring of CP-treated fathers showed a decrease in fetal ovary germ cells, in estrous cycle length and FSH levels, and an increase in the percentage of antral follicles in adults. Based on our previous results and the findings of the present work we concluded that CP-paternal exposure leads to adverse effects on rat male and female reproductive development, raising concern, in humans, for children born to men exposed to CP.


Asunto(s)
Antineoplásicos/toxicidad , Cisplatino/toxicidad , Exposición Paterna , Efectos Tardíos de la Exposición Prenatal , Diferenciación Sexual/efectos de los fármacos , Animales , Ciclo Estral/efectos de los fármacos , Femenino , Fertilidad/efectos de los fármacos , Hormona Folículo Estimulante/sangre , Células Germinativas/efectos de los fármacos , Masculino , Ovario/efectos de los fármacos , Embarazo , Ratas Wistar , Conducta Sexual Animal/efectos de los fármacos
8.
J Toxicol Environ Health A ; 78(20): 1288-98, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26488366

RESUMEN

Interferon-alpha (IFN- α), a type I IFN, is a protein with antiviral, antiproliferative, and immunoregulatory activities, widely used in the treatment of several types of cancers as well as hepatitis B and C. Decrease of libido and erectile dysfunction are commonly reported by male patients during treatment of chronic hepatitis C with IFN- α . However, IFN therapy-associated underlying factors attributed to sexual dysfunction are still not well defined. Currently, there are few studies investigating the effects of IFN on male reproductive system functions. Given that, the aim of the present investigation was to examine effects of subchronic exposure to IFN- α (5 × 10(4) U/kg and 10 × 10(4) U/kg, 30 d) on serum hormones, sperm parameters, fertility, and testicular and epididymal hystopathology and morphometry in adult male Wistar rats. None of the evaluated parameters was markedly altered by IFN- α . Thus, our results suggest that exposure to IFN- α , in this experimental design, did not adversely affect sperm quality and fertile capacity of male rats.


Asunto(s)
Antivirales/toxicidad , Interferón-alfa/toxicidad , Reproducción/efectos de los fármacos , Animales , Antivirales/administración & dosificación , Relación Dosis-Respuesta a Droga , Epidídimo/anatomía & histología , Epidídimo/efectos de los fármacos , Fertilidad/efectos de los fármacos , Hormonas/sangre , Interferón-alfa/administración & dosificación , Masculino , Distribución Aleatoria , Ratas , Ratas Wistar , Espermatozoides/efectos de los fármacos , Espermatozoides/fisiología , Testículo/anatomía & histología , Testículo/efectos de los fármacos , Pruebas de Toxicidad Subcrónica
9.
J Toxicol Environ Health A ; 78(8): 481-91, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25849765

RESUMEN

Prochloraz (PCZ) is a fungicide and androgen-receptor antagonist used worldwide in horticulture and agriculture. Pre- and perinatal exposure to this pesticide during sexual differentiation is deleterious for male offspring. Since data on the effects of PCZ on epididymal functions are scarce, and because sperm maturation occurs in this organ, the present investigation aimed to determine whether low PCZ doses administered to rats during the phase of sperm transit through the epididymis might affect the morphophysiology of this organ and sperm quality. Adult male Wistar rats were assigned to 4 different groups: 0 (control, vehicle) or 10, 15, or 30 mg/kg bw/d PCZ diluted in corn oil administered orally for 4 consecutive days. Morphofunctional parameters of the male reproductive tract, hormone concentrations, sperm evaluations, and fertility and histopathologic analysis of testis and epididymis were assessed. There were no statistically significant differences between treated and control groups in relation to all evaluated parameters. Data demonstrated show that PCZ exposure for a brief 4-d exposure and low doses did not produce reproductive toxicity or compromise sperm quality in adult rats.


Asunto(s)
Antagonistas de Andrógenos/toxicidad , Epidídimo/efectos de los fármacos , Fertilidad/efectos de los fármacos , Fungicidas Industriales/toxicidad , Imidazoles/toxicidad , Espermatogénesis/efectos de los fármacos , Testículo/efectos de los fármacos , Administración Oral , Antagonistas de Andrógenos/efectos adversos , Animales , Peso Corporal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Epidídimo/citología , Epidídimo/crecimiento & desarrollo , Femenino , Fungicidas Industriales/administración & dosificación , Humanos , Imidazoles/administración & dosificación , Inseminación Artificial , Masculino , Tamaño de los Órganos/efectos de los fármacos , Distribución Aleatoria , Ratas Wistar , Análisis de Semen , Testículo/citología , Testículo/crecimiento & desarrollo , Pruebas de Toxicidad Subaguda
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA